The immunoregulatory role of type i and type II NKT cells in cancer and other diseases

Cancer Immunology, Immunotherapy

Volumn 63, Issue 3, 2014, Pages 199-213

  Terabe, Masaki ^a   Berzofsky, Jay A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Interaction among regulatory cells; NKT cells; Regulatory T cells (Treg); Tumor immunity

Indexed keywords

ANIMALS; ANTIGENS, NEOPLASM; CELL COMMUNICATION; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY, ADOPTIVE; LIPIDS; NATURAL KILLER T-CELLS; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84894471037     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1509-4     Document Type: Review

References (122)

1. Cheever MA, Higano CS (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17:3520-3526. doi: 10.1158/1078-0432.CCR-10-3126
2. Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723. doi: 10.1056/NEJMoa1003466
3. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162-174. doi: 10.1038/nri2506
4. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127:759-767. doi: 10.1002/ijc.25429
5. Terabe M, Berzofsky JA (2008) The role of NKT cells in tumor immunity. Adv Cancer Res 101:277-348
6. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK (2012) Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22:275-281. doi: 10.1016/j.semcancer.2012.01.011
7. Liu D, Song L, Wei J et al (2012) IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. J Clin Invest 122:2221-2233. doi: 10.1172/JCI59535
8. Frentsch M, Stark R, Matzmohr N et al (2013) CD40L expression permits CD8 + T cells to execute immunologic helper functions. Blood 122:405-412. doi: 10.1182/blood-2013-02-483586
9. Mussai F, De Santo C, Cerundolo V (2012) Interaction between invariant NKT cells and myeloid-derived suppressor cells in cancer patients: evidence and therapeutic opportunities. J Immunother 35:449-459. doi: 10.1097/CJI. 0b013e31825be926
10. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ (2013) The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 138:105-115. doi: 10.1111/imm.12036
11. Bendelac A, Savage PB, Teyton L (2007) The biology of NKT cells. Annu Rev Immunol 25:297-336
12. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H (2003) The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21:483-513
13. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L (2004) NKT cells: what's in a name? Nat Rev Immunol 4:231-237
14. Bai L, Picard D, Anderson B, Chaudhary V, Luoma A, Jabri B, Adams EJ, Savage PB, Bendelac A (2012) The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vdelta1 TCR. Eur J Immunol 42:2505-2510. doi: 10.1002/eji.201242531
15. Tupin E, Kinjo Y, Kronenberg M (2007) The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 5:405-417
16. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR (2005) Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol 35:1692-1701
17. Girardi E, Zajonc DM (2012) Molecular basis of lipid antigen presentation by CD1d and recognition by natural killer T cells. Immunol Rev 250:167-179. doi: 10.1111/j.1600-065X.2012.01166.x
18. Cox D, Fox L, Tian R, Bardet W, Skaley M, Mojsilovic D, Gumperz J, Hildebrand W (2009) Determination of cellular lipids bound to human CD1d molecules. PLoS ONE 4:e5325. doi: 10.1371/journal.pone.0005325
19. Yuan W, Kang SJ, Evans JE, Cresswell P (2009) Natural lipid ligands associated with human CD1d targeted to different subcellular compartments. J Immunol 182:4784-4791. doi: 10.4049/jimmunol.0803981
20. Pei B, Speak AO, Shepherd D, Butters T, Cerundolo V, Platt FM, Kronenberg M (2011) Diverse endogenous antigens for mouse NKT cells: self-antigens that are not glycosphingolipids. J Immunol 186:1348-1360. doi: 10.4049/jimmunol. 1001008
21. Gumperz JE, Roy C, Makowska A et al (2000) Murine CD1d-restricted T cell recognition of cellular lipids. Immunity 12:211-221
22. Fox LM, Cox DG, Lockridge JL et al (2009) Recognition of lyso-phospholipids by human natural killer T lymphocytes. PLoS Biol 7:e1000228
23. Zhou D, Mattner J, Cantu C 3rd et al (2004) Lysosomal glycosphingolipid recognition by NKT cells. Science 306:1786-1789
24. Christiansen D, Milland J, Mouhtouris E, Vaughan H, Pellicci DG, McConville MJ, Godfrey DI, Sandrin MS (2008) Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation. PLoS Biol 6:e172. doi: 10.1371/journal.pbio.0060172
25. Porubsky S, Speak AO, Luckow B, Cerundolo V, Platt FM, Grone HJ (2007) Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc Natl Acad Sci USA 104:5977-5982
26. Porubsky S, Speak AO, Salio M et al (2012) Globosides but not isoglobosides can impact the development of invariant NKT cells and their interaction with dendritic cells. J Immunol 189:3007-3017. doi: 10.4049/jimmunol.1201483
27. Brennan PJ, Tatituri RV, Brigl M et al (2011) Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat Immunol 12:1203-1211. doi: 10.1038/ni.2143
28. Rhost S, Lofbom L, Rynmark BM, Pei B, Mansson JE, Teneberg S, Blomqvist M, Cardell SL (2012) Identification of novel glycolipid ligands activating a sulfatide-reactive, CD1d-restricted, type II natural killer T lymphocyte. Eur J Immunol 42:2851-2860. doi: 10.1002/eji.201142350
29. Tatituri RV, Watts GF, Bhowruth V et al (2013) Recognition of microbial and mammalian phospholipid antigens by NKT cells with diverse TCRs. Proc Natl Acad Sci USA 110:1827-1832. doi: 10.1073/pnas.1220601110
30. Dieude M, Striegl H, Tyznik AJ, Wang J, Behar SM, Piccirillo CA, Levine JS, Zajonc DM, Rauch J (2011) Cardiolipin binds to CD1d and stimulates CD1d-restricted gammadelta T cells in the normal murine repertoire. J Immunol 186:4771-4781. doi: 10.4049/jimmunol.1000921
31. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB (2003) Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 198:173-181
32. Webb TJ, Li X, Giuntoli RL 2nd et al (2012) Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res 72:3744-3752. doi: 10.1158/0008-5472.CAN-11-2695
33. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V (2004) Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 199:947-957
34. Roberts DD (1986) Sulfatide-binding proteins. Chem Phys Lipids 42:173-183
35. Blomqvist M, Rhost S, Teneberg S, Lofbom L, Osterbye T, Brigl M, Mansson JE, Cardell SL (2009) Multiple tissue-specific isoforms of sulfatide activate CD1d-restricted type II NKT cells. Eur J Immunol 39:1726-1735
36. Chang DH, Deng H, Matthews P et al (2008) Inflammation associated lysophospholipids as ligands for CD1d restricted T cells in human cancer. Blood 112:1308-1316
37. Salio M, Cerundolo V (2009) Linking inflammation to natural killer T cell activation. PLoS Biol 7:e1000226. doi: 10.1371/journal.pbio.1000226
38. Darmoise A, Teneberg S, Bouzonville L, Brady RO, Beck M, Kaufmann SH, Winau F (2010) Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells. Immunity 33:216-228. doi: 10.1016/j.immuni.2010.08.003
39. Salio M, Speak AO, Shepherd D, Polzella P, Illarionov PA, Veerapen N, Besra GS, Platt FM, Cerundolo V (2007) Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proc Natl Acad Sci USA 104:20490-20495
40. Paget C, Chow MT, Duret H, Mattarollo SR, Smyth MJ (2012) Role of gammadelta T cells in alpha-galactosylceramide-mediated immunity. J Immunol 188:3928-3939. doi: 10.4049/jimmunol.1103582
41. Taraban VY, Martin S, Attfield KE, Glennie MJ, Elliott T, Elewaut D, Van Calenbergh S, Linclau B, Al-Shamkhani A (2008) Invariant NKT cells promote CD8 + cytotoxic T cell responses by inducing CD70 expression on dendritic cells. J Immunol 180:4615-4620
42. Semmling V, Lukacs-Kornek V, Thaiss CA et al (2010) Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol. doi: 10.1038/ni.1848
43. Fujii S, Shimizu K, Hemmi H, Steinman RM (2007) Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev 220:183-198
44. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC et al (2002) Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195:617-624
45. Silk JD, Hermans IF, Gileadi U et al (2004) Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 114:1800-1811
46. Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S (2007) Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 204:2641-2653
47. Motohashi S, Okamoto Y, Nakayama T (2011) Clinical Trials of Invariant Natural Killer T cell-Based Immunotherapy for Cancer. In: Terabe M, Berzofsky JA (eds) Natural killer T cells: balancing the regulation of tumor immunity. Springer, LLC, pp 169-184
48. Schneiders FL, Scheper RJ, Bontkes HJ, von Blomberg BM, van den Eertwegh AJ, de Gruijl TD, van der Vliet HJ (2011) Clinical trials with a-galactosylceramide (KRN7000) in advanced cancer. In: Terabe M, Berzofsky JA (eds) Natural killer T cells: balancing the regulation of tumor immunity. Springer, LLC, pp 169-184
49. Ishikawa A, Motohashi S, Ishikawa E et al (2005) A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11:1910-1917
50. Nieda M, Okai M, Tazbirkova A et al (2004) Therapeutic activation of Valpha24 + Vbeta11 + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103:383-389
51. Uchida T, Horiguchi S, Tanaka Y, Yamamoto H, Kunii N, Motohashi S, Taniguchi M, Nakayama T, Okamoto Y (2008) Phase I study of alpha- galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 57:337-345
52. O'Konek JJ, Illarionov P, Khursigara DS et al (2011) Mouse and human iNKT cell agonist beta-mannosylceramide reveals a distinct mechanism of tumor immunity. J Clin Invest 121:683-694. doi: 10.1172/JCI42314
53. O'Konek JJ, Kato S, Takao S, Izhak L, Xia Z, Illarionov P, Besra GS, Terabe M, Berzosfky JA (2013) Beta-mannosylceramide activates type I natural killer T cells to induce tumor immunity without inducing long-term functional anergy. Clin Cancer Res 19:4404-4411. doi: 10.1158/1078-0432.CCR-12-2169
54. Mattarollo SR, West AC, Steegh K et al (2012) NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood 120:3019-3029. doi: 10.1182/blood-2012-04-426643
55. Smyth MJ, Thia KY, Street SE et al (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191:661-668
56. Swann JB, Uldrich AP, van Dommelen S, Sharkey J, Murray WK, Godfrey DI, Smyth MJ (2009) Type I natural killer T cells suppress tumors caused by p53 loss in mice. Blood 113:6382-6385
57. Bellone M, Ceccon M, Grioni M, Jachetti E, Calcinotto A, Napolitano A, Freschi M, Casorati G, Dellabona P (2010) iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells. PLoS ONE 5:e8646
58. Crowe NY, Smyth MJ, Godfrey DI (2002) A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas. J Exp Med 196:119-127
59. Dhodapkar MV, Geller MD, Chang DH, Shimizu K, Fujii S, Dhodapkar KM, Krasovsky J (2003) A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197:1667-1676
60. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG, Hayakawa Y, Godfrey DI, Smyth MJ (2005) Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 202:1279-1288
61. Giaccone G, Punt CJ, Ando Y et al (2002) A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8:3702-3709
62. Molling JW, Langius JA, Langendijk JA, Leemans CR, Bontkes HJ, van der Vliet HJ, von Blomberg BM, Scheper RJ, van den Eertwegh AJ (2007) Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 25:862-868
63. Najera Chuc AE, Cervantes LA, Retiguin FP, Ojeda JV, Maldonado ER (2012) Low number of invariant NKT cells is associated with poor survival in acute myeloid leukemia. J Cancer Res Clin Oncol 138:1427-1432. doi: 10.1007/s00432-012-1251-x
64. Tachibana T, Onodera H, Tsuruyama T, Mori A, Nagayama S, Hiai H, Imamura M (2005) Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 11:7322-7327
65. Yang W, Li H, Mayhew E, Mellon J, Chen PW, Niederkorn JY (2011) NKT cell exacerbation of liver metastases arising from melanomas transplanted into either the eyes or spleens of mice. Invest Ophthalmol Vis Sci 52:3094-3102. doi: 10.1167/iovs.10-7067
66. Bjordahl RL, Gapin L, Marrack P, Refaeli Y (2012) iNKT cells suppress the CD8 + T cell response to a murine Burkitt's-like B cell lymphoma. PLoS ONE 7:e42635. doi: 10.1371/journal.pone.0042635
67. Terabe M, Swann J, Ambrosino E et al (2005) A nonclassical non-Va14Ja18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 202:1627-1633
68. Renukaradhya GJ, Sriram V, Du W, Gervay-Hague J, Van Kaer L, Brutkiewicz RR (2006) Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo. Int J Cancer 118:3045-3053
69. Nowak M, Arredouani MS, Tun-Kyi A, Schmidt-Wolf I, Sanda MG, Balk SP, Exley MA (2010) Defective NKT cell activation by CD1d + TRAMP prostate tumor cells is corrected by interleukin-12 with alpha-galactosylceramide. PLoS ONE 5:e11311. doi: 10.1371/journal.pone.0011311
70. Hix LM, Shi YH, Brutkiewicz RR, Stein PL, Wang CR, Zhang M (2011) CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis. PLoS ONE 6:e20702. doi: 10.1371/journal.pone.0020702
71. Skold M, Faizunnessa NN, Wang CR, Cardell S (2000) CD1d-specific NK1.1 + T cells with a transgenic variant TCR. J Immunol 165:168-174
72. Duarte N, Stenstrom M, Campino S, Bergman ML, Lundholm M, Holmberg D, Cardell SL (2004) Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells. J Immunol 173:3112-3118
73. Kadri N, Korpos E, Gupta S et al (2012) CD4(+) type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes. J Immunol 188:3138-3149. doi: 10.4049/jimmunol.1101390
74. Subramanian L, Blumenfeld H, Tohn R et al (2012) NKT cells stimulated by long fatty acyl chain sulfatides significantly reduce the incidence of type 1 diabetes in nonobese diabetic mice [corrected]. PLoS ONE 7:e37771. doi: 10.1371/journal.pone.0037771
75. Halder RC, Aguilera C, Maricic I, Kumar V (2007) Type II NK T cell-mediated anergy induction in type I NK T cells prevents inflammatory liver disease. J Clin Invest 117:2302-2312
76. Baron V, Bouneaud C, Cumano A, Lim A, Arstila TP, Kourilsky P, Ferradini L, Pannetier C (2003) The repertoires of circulating human CD8(+) central and effector memory T cell subsets are largely distinct. Immunity 18:193-204
77. Arrenberg P, Maricic I, Kumar V (2011) Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice. Gastroenterology 140:646-655. doi: 10.1053/j.gastro.2010.10.003
78. Zhang G, Nie H, Yang J, Ding X, Huang Y, Yu H, Li R, Yuan Z, Hu S (2011) Sulfatide-activated type II NKT cells prevent allergic airway inflammation by inhibiting type I NKT cell function in a mouse model of asthma. Am J Physiol Lung Cell Mol Physiol 301:L975-L984. doi: 10.1152/ajplung.0 0114.2011
79. Kwiecinski J, Rhost S, Lofbom L, Blomqvist M, Mansson JE, Cardell SL, Jin T (2013) Sulfatide attenuates experimental Staphylococcus aureus sepsis through a CD1d-dependent pathway. Infect Immun 81:1114-1120. doi: 10.1128/IAI.01334-12
80. Yang SH, Lee JP, Jang HR et al (2011) Sulfatide-reactive natural killer T cells abrogate ischemia-reperfusion injury. J Am Soc Nephrol 22:1305-1314. doi: 10.1681/ASN.2010080815
81. Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ (2005) Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect Immun 73:181-192
82. Mallevaey T, Fontaine J, Breuilh L et al (2007) Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis. Infect Immun 75:2171-2180
83. Brandl C, Ortler S, Herrmann T, Cardell S, Lutz MB, Wiendl H (2010) B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells. PLoS ONE 5:e10800. doi: 10.1371/journal.pone.0010800
84. Kim JH, Choi EY, Chung DH (2007) Donor bone marrow type II (non-Valpha14Jalpha18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-gamma and IL-4. J Immunol 179:6579-6587
85. Renukaradhya GJ, Khan MA, Vieira M, Du W, Gervay-Hague J, Brutkiewicz RR (2008) Type I NKT cells protect (and type II NKT cells suppress) the host's innate antitumor immune response to a B-cell lymphoma. Blood 111:5637-5645
86. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, Carbone DP, Paul WE, Berzofsky JA (2000) NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 1:515-520
87. Terabe M, Matsui S, Park J-M et al (2003) Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 198:1741-1752
88. Ambrosino E, Terabe M, Halder RC, Peng J, Takaku S, Miyake S, Yamamura T, Kumar V, Berzofsky JA (2007) Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 179:5126-5136
89. Terabe M, Berzofsky JA (2007) NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol 28:491-496
90. Berzofsky JA, Terabe M (2008) NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol 180:3627-3635
91. Izhak L, Ambrosino E, Kato S et al (2013) Delicate balance among three types of T cells in concurrent regulation of tumor immunity. Cancer Res 73:1514-1523. doi: 10.1158/0008-5472.CAN-12-2567
92. Akbari O, Stock P, Meyer E et al (2003) Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 9:582-588
93. Akbari O, Faul JL, Hoyte EG, Berry GJ, Wahlstrom J, Kronenberg M, DeKruyff RH, Umetsu DT (2006) CD4 + invariant T-cell-receptor + natural killer T cells in bronchial asthma. N Engl J Med 354:1117-1129
94. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151-1164
95. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128-3133
96. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR (2013) Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 171:36-45. doi: 10.1111/j.1365-2249.2012.04657.x
97. Terabe M, Berzofsky JA (2004) Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 16:157-162
98. Liu R, La Cava A, Bai XF et al (2005) Cooperation of invariant NKT cells and CD4 + CD25 + T regulatory cells in the prevention of autoimmune myasthenia. J Immunol 175:7898-7904
99. Jiang S, Game DS, Davies D, Lombardi G, Lechler RI (2005) Activated CD1d-restricted natural killer T cells secrete IL-2: innate help for CD4 + CD25 + regulatory T cells? Eur J Immunol 35:1193-1200
100. Shi FD, Wang HB, Li H, Hong S, Taniguchi M, Link H, Van Kaer L, Ljunggren HG (2000) Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 1:245-251. doi: 10.1038/79792
101. Ronet C, Darche S, Leite de Moraes M, Miyake S, Yamamura T, Louis JA, Kasper LH, Buzoni-Gatel D (2005) NKT cells are critical for the initiation of an inflammatory bowel response against Toxoplasma gondii. J Immunol 175:899-908
102. Burdin N, Brossay L, Kronenberg M (1999) Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 29:2014-2025
103. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR, Joyce S, Van Kaer L (2005) Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 115:2572-2583
104. Santodomingo-Garzon T, Han J, Le T, Yang Y, Swain MG (2009) Natural killer T cells regulate the homing of chemokine CXC receptor 3-positive regulatory T cells to the liver in mice. Hepatology 49:1267-1276. doi: 10.1002/hep.22761
105. Roelofs-Haarhuis K, Wu X, Nowak M, Fang M, Artik S, Gleichmann E (2003) Infectious nickel tolerance: a reciprocal interplay of tolerogenic APCs and T suppressor cells that is driven by immunization. J Immunol 171:2863-2872
106. Diana J, Brezar V, Beaudoin L et al (2011) Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay. J Exp Med 208:729-745. doi: 10.1084/jem.20101692
107. Chang YJ, Kim HY, Albacker LA et al (2011) Influenza infection in suckling mice expands an NKT cell subset that protects against airway hyperreactivity. J Clin Invest 121:57-69. doi: 10.1172/JCI44845
108. Kohrt HE, Pillai AB, Lowsky R, Strober S (2010) NKT cells, Treg, and their interactions in bone marrow transplantation. Eur J Immunol 40:1862-1869. doi: 10.1002/eji.201040394
109. Hongo D, Tang X, Dutt S, Nador RG, Strober S (2012) Interactions between NKT cells and Tregs are required for tolerance to combined bone marrow and organ transplants. Blood 119:1581-1589. doi: 10.1182/blood-2011-08-371948
110. Kohrt HE, Turnbull BB, Heydari K et al (2009) TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 114:1099-1109. doi: 10.1182/blood-2009-03-211441
111. Lowsky R, Takahashi T, Liu YP et al (2005) Protective conditioning for acute graft-versus-host disease. N Engl J Med 353:1321-1331. doi: 10.1056/NEJMoa050642
112. Vela-Ojeda J, Montiel-Cervantes L, Granados-Lara P et al (2010) Role of CD4 + CD25 + highFoxp3 + CD62L + regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation. Stem Cells Dev 19:333-340. doi: 10.1089/scd 2009.0216
113. Oh KH, Lee C, Lee SW, Jeon SH, Park SH, Seong RH, Hong S (2011) Activation of natural killer T cells inhibits the development of induced regulatory T cells via IFNgamma. Biochem Biophys Res Commun 411:599-606. doi: 10.1016/j.bbrc.2011.06.193
114. Nguyen KD, Vanichsarn C, Nadeau KC (2008) Increased cytotoxicity of CD4 + invariant NKT cells against CD4 + CD25hiCD127lo/- regulatory T cells in allergic asthma. Eur J Immunol 38:2034-2045. doi: 10.1002/eji.200738082
115. Thorburn AN, Foster PS, Gibson PG, Hansbro PM (2012) Components of Streptococcus pneumoniae suppress allergic airways disease and NKT cells by inducing regulatory T cells. J Immunol 188:4611-4620. doi: 10.4049/jimmunol. 1101299
116. Nishikawa H, Kato T, Tanida K et al (2003) CD4 + CD25 + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 100:10902-10906
117. Azuma T, Takahashi T, Kunisato A, Kitamura T, Hirai H (2003) Human CD4 + CD25 + regulatory T cells suppress NKT cell functions. Cancer Res 63:4516-4520
118. Venken K, Decruy T, Aspeslagh S, Van Calenbergh S, Lambrecht BN, Elewaut D (2013) Bacterial CD1d-restricted glycolipids induce IL-10 production by human regulatory T cells upon cross-talk with invariant NKT cells. J Immunol 191:2174-2183. doi: 10.4049/jimmunol.1300562
119. Petersen TR, Sika-Paotonu D, Knight DA, Dickgreber N, Farrand KJ, Ronchese F, Hermans IF (2010) Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand. Immunol Cell Biol 88:596-604. doi: 10.1038/icb.2010.9
120. Mattarollo SR, Steegh K, Li M, Duret H, Ngiow SF, Smyth MJ (2013) Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells. Immunol Cell Biol 91:105-114. doi: 10.1038/icb.2012.58
121. Pere H, Tanchot C, Bayry J et al (2012) Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology 1:326-333. doi: 10.4161/onci.18852
122. Golgher D, Jones E, Powrie F, Elliott T, Gallimore A (2002) Depletion of CD25 + regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 32:3267-3275